Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Quantitative Systems Pharmacology Model of a Masked, Tumor-Activated Antibody.

Stroh M, Sagert J, Burke JM, Apgar JF, Lin L, Millard BL, Michael Kavanaugh W.

CPT Pharmacometrics Syst Pharmacol. 2019 Sep;8(9):676-684. doi: 10.1002/psp4.12448. Epub 2019 Jul 26.

2.

A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients.

Netterberg I, Li CC, Molinero L, Budha N, Sukumaran S, Stroh M, Jonsson EN, Friberg LE.

Clin Pharmacol Ther. 2019 Feb;105(2):486-495. doi: 10.1002/cpt.1198. Epub 2018 Sep 4.

3.

A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics.

Claret L, Jin JY, Ferté C, Winter H, Girish S, Stroh M, He P, Ballinger M, Sandler A, Joshi A, Rittmeyer A, Gandara D, Soria JC, Bruno R.

Clin Cancer Res. 2018 Jul 15;24(14):3292-3298. doi: 10.1158/1078-0432.CCR-17-3662. Epub 2018 Apr 23.

4.

Designing In and Around Tolerability Considerations for Immunotherapy Combinations.

Stroh M.

Clin Pharmacol Ther. 2018 Apr;103(4):558-561. doi: 10.1002/cpt.945. Epub 2017 Dec 11.

PMID:
29226337
5.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Oct;22(10):1281. doi: 10.1634/theoncologist.2016-0133erratum. No abstract available.

6.

NCB5OR Deficiency in the Cerebellum and Midbrain Leads to Dehydration and Alterations in Thirst Response, Fasted Feeding Behavior, and Voluntary Exercise in Mice.

Stroh MA, Winter MK, McCarson KE, Thyfault JP, Zhu H.

Cerebellum. 2018 Apr;17(2):152-164. doi: 10.1007/s12311-017-0880-7.

PMID:
28887630
7.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H.

Oncologist. 2017 Apr;22(4):375-e30. doi: 10.1634/theoncologist.2016-0133. Epub 2017 Mar 8. Erratum in: Oncologist. 2017 Oct;22(10 ):1281.

8.

Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.

Han K, Chanu P, Jonsson F, Winter H, Bruno R, Jin J, Stroh M.

AAPS J. 2017 Mar;19(2):527-533. doi: 10.1208/s12248-016-0029-5. Epub 2016 Dec 27.

PMID:
28028730
9.

Clinical Pharmacokinetics and Pharmacodynamics of Atezolizumab in Metastatic Urothelial Carcinoma.

Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, Abidoye O, Teng SL, Lin WT, Dayog S, Bruno R, Jin J, Girish S.

Clin Pharmacol Ther. 2017 Aug;102(2):305-312. doi: 10.1002/cpt.587. Epub 2017 Jun 9. Review.

PMID:
27981577
10.

Loss of NCB5OR in the cerebellum disturbs iron pathways, potentiates behavioral abnormalities, and exacerbates harmaline-induced tremor in mice.

Stroh MA, Winter MK, Swerdlow RH, McCarson KE, Zhu H.

Metab Brain Dis. 2016 Aug;31(4):951-64. doi: 10.1007/s11011-016-9834-x. Epub 2016 May 18.

11.

Should Therapeutic Drug Monitoring for Monoclonal Antibodies Remain the Exception or Become the Norm?

Stroh M, Lum BL.

Clin Pharmacol Ther. 2016 Sep;100(3):215-7. doi: 10.1002/cpt.365. Epub 2016 May 3.

PMID:
26971373
12.

A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities.

Lu D, Lu T, Stroh M, Graham RA, Agarwal P, Musib L, Li CC, Lum BL, Joshi A.

Cancer Chemother Pharmacol. 2016 Mar;77(3):459-76. doi: 10.1007/s00280-015-2931-4. Epub 2016 Jan 25. Review.

13.

Meta-analysis of published efficacy and safety data for docetaxel in second-line treatment of patients with advanced non-small-cell lung cancer.

Stroh M, Green M, Cha E, Zhang N, Wada R, Jin J.

Cancer Chemother Pharmacol. 2016 Mar;77(3):485-94. doi: 10.1007/s00280-015-2957-7. Epub 2016 Jan 12.

PMID:
26758586
14.

Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue.

Stroh M, Carlile DJ, Li CC, Wagg J, Ribba B, Ramanujan S, Jin J, Xu J, Charoin JE, Xhu ZX, Morcos PN, Davis JD, Phipps A.

CPT Pharmacometrics Syst Pharmacol. 2015 Sep;4(9):495-7. doi: 10.1002/psp4.12014. Epub 2015 Sep 11.

15.

Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.

Borin MT, Chen M, Mocci S, Rubets I, Chittenden J, Aldairy W, Stroh M.

Cancer Chemother Pharmacol. 2015 Feb;75(2):401-10. doi: 10.1007/s00280-014-2652-0. Epub 2014 Dec 27.

PMID:
25542267
16.

Translation of anticancer efficacy from nonclinical models to the clinic.

Stroh M, Duda DG, Takimoto CH, Yamazaki S, Vicini P.

CPT Pharmacometrics Syst Pharmacol. 2014 Aug 6;3:e128. doi: 10.1038/psp.2014.28.

17.

Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation.

Stroh M, Talaty J, Sandhu P, McCrea J, Patnaik A, Tolcher A, Palcza J, Orford K, Breidinger S, Narasimhan N, Panebianco D, Lush R, Papadopoulos KP, Wagner JA, Trucksis M, Agrawal N.

J Clin Pharmacol. 2014 Nov;54(11):1256-62. doi: 10.1002/jcph.331. Epub 2014 May 24.

PMID:
24827931
18.

Common defects of mitochondria and iron in neurodegeneration and diabetes (MIND): a paradigm worth exploring.

Stroh M, Swerdlow RH, Zhu H.

Biochem Pharmacol. 2014 Apr 15;88(4):573-83. doi: 10.1016/j.bcp.2013.11.022. Epub 2013 Dec 19. Review.

19.

Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans.

Gibson CR, Lu P, Maciolek C, Wudarski C, Barter Z, Rowland-Yeo K, Stroh M, Lai E, Nicoll-Griffith DA.

Xenobiotica. 2013 Dec;43(12):1027-36. doi: 10.3109/00498254.2013.791761. Epub 2013 May 3.

PMID:
23641955
20.

Simultaneous pharmacokinetic model for rolofylline and both M1-trans and M1-cis metabolites.

Stroh M, Hutmacher MM, Pang J, Lutz R, Magara H, Stone J.

AAPS J. 2013 Apr;15(2):498-504. doi: 10.1208/s12248-012-9443-5. Epub 2013 Jan 25.

21.

Do attachment representations predict depression and anxiety in psychiatrically hospitalized prepubertal children?

Goodman G, Stroh M, Valdez A.

Bull Menninger Clin. 2012 Summer;76(3):260-89.

PMID:
22988901
22.

A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.

Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A.

Cancer Chemother Pharmacol. 2012 Oct;70(4):567-74. Epub 2012 Aug 10.

23.

The minimal impact of food on the pharmacokinetics of ridaforolimus.

Stroh M, Li X, Marsilio S, Panebianco D, Johnson-Levonas A, Juan A, Orford K, Agrawal N, Trucksis M, Wagner JA, Murphy G, Iwamoto M.

Cancer Chemother Pharmacol. 2012 Jul;70(1):177-82. doi: 10.1007/s00280-012-1897-8. Epub 2012 Jun 6.

PMID:
22669570
24.

Operating room traffic is a major concern during total joint arthroplasty.

Panahi P, Stroh M, Casper DS, Parvizi J, Austin MS.

Clin Orthop Relat Res. 2012 Oct;470(10):2690-4.

25.

The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.

Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M.

Cancer Chemother Pharmacol. 2012 May;69(5):1247-53. doi: 10.1007/s00280-011-1819-1.

PMID:
22290273
26.

RNA-induced silencing complex-bound small interfering RNA is a determinant of RNA interference-mediated gene silencing in mice.

Wei J, Jones J, Kang J, Card A, Krimm M, Hancock P, Pei Y, Ason B, Payson E, Dubinina N, Cancilla M, Stroh M, Burchard J, Sachs AB, Hochman JH, Flanagan WM, Kuklin NA.

Mol Pharmacol. 2011 Jun;79(6):953-63. doi: 10.1124/mol.110.070409. Epub 2011 Mar 22.

PMID:
21427169
27.

Gamma-ray emission concurrent with the nova in the symbiotic binary V407 Cygni.

Fermi-LAT Collaboration, Abdo AA, Ackermann M, Ajello M, Atwood WB, Baldini L, Ballet J, Barbiellini G, Bastieri D, Bechtol K, Bellazzini R, Berenji B, Blandford RD, Bloom ED, Bonamente E, Borgland AW, Bouvier A, Brandt TJ, Bregeon J, Brez A, Brigida M, Bruel P, Buehler R, Burnett TH, Buson S, Caliandro GA, Cameron RA, Caraveo PA, Carrigan S, Casandjian JM, Cecchi C, Celik O, Charles E, Chaty S, Chekhtman A, Cheung CC, Chiang J, Ciprini S, Claus R, Cohen-Tanugi J, Conrad J, Corbel S, Corbet R, DeCesar ME, den Hartog PR, Dermer CD, de Palma F, Digel SW, Donato D, do Couto e Silva E, Drell PS, Dubois R, Dubus G, Dumora D, Favuzzi C, Fegan SJ, Ferrara EC, Fortin P, Frailis M, Fuhrmann L, Fukazawa Y, Funk S, Fusco P, Gargano F, Gasparrini D, Gehrels N, Germani S, Giglietto N, Giordano F, Giroletti M, Glanzman T, Godfrey G, Grenier IA, Grondin MH, Grove JE, Guiriec S, Hadasch D, Harding AK, Hayashida M, Hays E, Healey SE, Hill AB, Horan D, Hughes RE, Itoh R, Jean P, Jóhannesson G, Johnson AS, Johnson RP, Johnson TJ, Johnson WN, Kamae T, Katagiri H, Kataoka J, Kerr M, Knödlseder J, Koerding E, Kuss M, Lande J, Latronico L, Lee SH, Lemoine-Goumard M, Garde ML, Longo F, Loparco F, Lott B, Lovellette MN, Lubrano P, Makeev A, Mazziotta MN, McConville W, McEnery JE, Mehault J, Michelson PF, Mizuno T, Moiseev AA, Monte C, Monzani ME, Morselli A, Moskalenko IV, Murgia S, Nakamori T, Naumann-Godo M, Nestoras I, Nolan PL, Norris JP, Nuss E, Ohno M, Ohsugi T, Okumura A, Omodei N, Orlando E, Ormes JF, Ozaki M, Paneque D, Panetta JH, Parent D, Pelassa V, Pepe M, Pesce-Rollins M, Piron F, Porter TA, Rainò S, Rando R, Ray PS, Razzano M, Razzaque S, Rea N, Reimer A, Reimer O, Reposeur T, Ripken J, Ritz S, Romani RW, Roth M, Sadrozinski HF, Sander A, Parkinson PM, Scargle JD, Schinzel FK, Sgrò C, Shaw MS, Siskind EJ, Smith DA, Smith PD, Sokolovsky KV, Spandre G, Spinelli P, Stawarz Ł, Strickman MS, Suson DJ, Takahashi H, Takahashi T, Tanaka T, Tanaka Y, Thayer JB, Thayer JG, Thompson DJ, Tibaldo L, Torres DF, Tosti G, Tramacere A, Uchiyama Y, Usher TL, Vandenbroucke J, Vasileiou V, Vilchez N, Vitale V, Waite AP, Wallace E, Wang P, Winer BL, Wolff MT, Wood KS, Yang Z, Ylinen T, Ziegler M, Maehara H, Nishiyama K, Kabashima F, Bach U, Bower GC, Falcone A, Forster JR, Henden A, Kawabata KS, Koubsky P, Mukai K, Nelson T, Oates SR, Sakimoto K, Sasada M, Shenavrin VI, Shore SN, Skinner GK, Sokoloski J, Stroh M, Tatarnikov AM, Uemura M, Wahlgren GM, Yamanaka M.

Science. 2010 Aug 13;329(5993):817-21. doi: 10.1126/science.1192537.

28.

The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.

Stroh M, Dishy V, Radziszewski W, Hwang E, Lazarus-Shipitofsky N, Dittrich H, Johnson-Levonas AO, Lutz R, Wagner JA, Lai E.

Am J Ther. 2010 Jan-Feb;17(1):53-60. doi: 10.1097/MJT.0b013e3181c12313.

PMID:
20027108
29.

A single supratherapeutic dose of rolofylline does not prolong the QTcF interval in healthy volunteers.

Radziszewski W, Lai E, Lazarus Shipitofsky N, Stroh M, Dishy V, Han L, Lewis W, Johnson-Levonas AO, Lutz R, Wagner J.

Am J Ther. 2010 Jan-Feb;17(1):8-16. doi: 10.1097/MJT.0b013e3181c3cbdb.

PMID:
20027105
30.

Effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the pharmacokinetics of rosiglitazone.

Schwartz JI, Stroh M, Gao B, Liu F, Rosko K, Zajic S, Meehan AJ, Ruckle J, Lai E, Wagner JA.

Cardiovasc Ther. 2009 Winter;27(4):239-45. doi: 10.1111/j.1755-5922.2009.00104.x.

PMID:
19903187
31.

Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.

Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring WJ, Ellenbogen A, Jinnah HA, Kirby L, Leibowitz MT, Stewart RM, Tarsy D, Tetrud J, Stoch SA, Gottesdiener K, Wagner J.

J Clin Pharmacol. 2009 Jul;49(7):856-64. doi: 10.1177/0091270009336735. Epub 2009 Jun 2.

PMID:
19491335
32.

Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.

Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.

Am J Ther. 2009 May-Jun;16(3):215-23. doi: 10.1097/MJT.0b013e31818f9c68.

PMID:
19454860
33.

Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency.

Stroh M, Wenning L, Luo WL, Desai R, Bi S, Keshavarz S, Lazarus N, Lunde NM, Smith WB, Schwartz M, Stone J, Wagner J, Lai E, Dishy V.

Am J Ther. 2009 Sep-Oct;16(5):379-84. doi: 10.1097/MJT.0b013e318197c59d.

PMID:
19433974
34.

Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event.

Stroh M, Addy C, Wu Y, Stoch SA, Pourkavoos N, Groff M, Xu Y, Wagner J, Gottesdiener K, Shadle C, Wang H, Manser K, Winchell GA, Stone JA.

AAPS J. 2009 Mar;11(1):99-108. doi: 10.1208/s12248-009-9083-6. Epub 2009 Feb 6.

35.

ADHD and aggression as correlates of suicidal behavior in assaultive prepubertal psychiatric inpatients.

Goodman G, Gerstadt C, Pfeffer CR, Stroh M, Valdez A.

Suicide Life Threat Behav. 2008 Feb;38(1):46-59. doi: 10.1521/suli.2008.38.1.46.

PMID:
18355108
36.

Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.

Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, Wagner JA, Macneil DJ, Heymsfield SB, Amatruda JM.

J Clin Endocrinol Metab. 2007 May;92(5):1754-7. Epub 2007 Mar 6.

PMID:
17341568
37.

X-ray flares in early GRB afterglows.

Burrows DN, Falcone A, Chincarini G, Morris D, Romano P, Hill JE, Godet O, Moretti A, Krimm H, Osborne JP, Racusin J, Mangano V, Page K, Perri M, Stroh M; Swift XRT Team.

Philos Trans A Math Phys Eng Sci. 2007 May 15;365(1854):1213-26.

PMID:
17293338
38.

Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo.

Stroh M, Zimmer JP, Duda DG, Levchenko TS, Cohen KS, Brown EB, Scadden DT, Torchilin VP, Bawendi MG, Fukumura D, Jain RK.

Nat Med. 2005 Jun;11(6):678-82. Epub 2005 May 8.

39.

Zooming in and out with quantum dots.

Jain RK, Stroh M.

Nat Biotechnol. 2004 Aug;22(8):959-60. No abstract available.

PMID:
15286644
40.

Multiphoton microscopy guides neurotrophin modification with poly(ethylene glycol) to enhance interstitial diffusion.

Stroh M, Zipfel WR, Williams RM, Ma SC, Webb WW, Saltzman WM.

Nat Mater. 2004 Jul;3(7):489-94. Epub 2004 Jun 20.

PMID:
15208704
41.

Diffusion of nerve growth factor in rat striatum as determined by multiphoton microscopy.

Stroh M, Zipfel WR, Williams RM, Webb WW, Saltzman WM.

Biophys J. 2003 Jul;85(1):581-8.

42.

Cholera toxin binding affinity and specificity for gangliosides determined by surface plasmon resonance.

Kuziemko GM, Stroh M, Stevens RC.

Biochemistry. 1996 May 21;35(20):6375-84.

PMID:
8639583
43.

A 'litmus test' for molecular recognition using artificial membranes.

Charych D, Cheng Q, Reichert A, Kuziemko G, Stroh M, Nagy JO, Spevak W, Stevens RC.

Chem Biol. 1996 Feb;3(2):113-20.

44.
45.

[Early operation for acute gallbladder as a therapeutic principle].

Maroske D, Stroh M, Röher HD.

Dtsch Med Wochenschr. 1985 Jul 12;110(28-29):1108-14. German.

PMID:
4006770
46.

[Indication and technic of interlocking nailing of the femur].

Maroske D, Thon K, Stroh M, Otto R.

Zentralbl Chir. 1984;109(9):577-91. German.

PMID:
6741322
47.

[Ender nailing of subcapital fractures of the femur neck (Garden I)].

Maroske D, Stroh M, Thon K, Drews H.

Zentralbl Chir. 1983;108(17):1095-104. German.

PMID:
6649960
48.

[Pediatric problems arising from surgery of the pancreas in childhood (author's transl)].

Hecker WC, Kraeft H, Ströh M.

Monatsschr Kinderheilkd. 1980 Dec;128(12):758-63. German.

PMID:
6109238

Supplemental Content

Support Center